By identifying genetic markers such as those in SLC6A3, DRD4, ADRA2A, COMT, DRD5, and SLC6A2 (Table 2), clinicians may be able to tailor ADHD treatment to individual patients, improving therapeutic outcomes and minimizing adverse effects. Here, DRD5 is linked to attention deficit-hyperactivity disorder.